Funding HIV-vaccine research in developing countries-what is wrong with IAVI's recommendation?

Authors:
Diana Sonntag

Health Econ 2014 Feb 28;23(2):141-58. Epub 2013 Jan 28.

Department of Medical Sociology and Health Economics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

The International AIDS Vaccine Initiative recommends targeting resources to research institutions in developing countries in order to accelerate the development of an effective HIV vaccine. In contrast, this paper shows that neither lump-sum nor in-kind transfers are an effective policy. We analyze several financing mechanisms as a means to overcome the lack of depth in HIV-vaccine research in a non-cooperative framework. At first, we point to cases in which financial support is actually counterproductive. Then we analyze whether in-kind transfers are preferable to lump-sum transfers. Even if donors prefer aid in kind because the incentives for moral hazard of recipients can be reduced, we demonstrate that it is effective only if recipients have cost advantages.

Download full-text PDF

Source
http://dx.doi.org/10.1002/hec.2909DOI Listing
February 2014
3 Reads

Publication Analysis

Top Keywords

in-kind transfers
8
aid kind
4
transfers effective
4
effective policy
4
policy analyze
4
prefer aid
4
analyze financing
4
lump-sum in-kind
4
paper lump-sum
4
support counterproductive
4
development effective
4
accelerate development
4
hiv vaccine
4
kind incentives
4
contrast paper
4
vaccine contrast
4
financing mechanisms
4
mechanisms overcome
4
point cases
4
transfers preferable
4

Similar Publications